Probiotics and NLRP3 mRNA inflammasome levels in women with endometriosis-related infertility undergoing assisted reproductive technologies

J Med Life. 2023 Oct;16(10):1439-1444. doi: 10.25122/jml-2023-0056.


This research was conducted at Bukovinian State Medical University and the Centre of Reproductive Medicine and included a total of 30 infertile women. The control group consisted of 10 women with tubal infertility resulting from a prior history of inflammation, who, following a comprehensive clinical and laboratory assessment, exhibited no other underlying health conditions and could be regarded as essentially healthy individuals. Participants in the control group ranged from 21 to 42 years, with an average age of 29.75 years. The control group did not receive the probiotic Femina Probiz. The main group, on the other hand, included 20 women diagnosed with external genital endometriosis who were undergoing assisted reproductive technologies. These patients were administered the probiotic Femina Probiz manufactured by Unic Biotech Ltd in India. They were instructed to take one tablet containing 10×10^9 Lactobacillus organisms twice daily for one month as part of their preparatory treatment before proceeding with assisted reproductive technologies. The levels of NLRP3 inflammasome were measured before and after this preparatory phase. The incidence of primary infertility was significantly higher in patients belonging to the main group.

Keywords: assisted reproductive technologies; endometriosis; inflammasome.

MeSH terms

  • Adult
  • Endometriosis* / complications
  • Female
  • Humans
  • Infertility, Female* / etiology
  • Infertility, Female* / therapy
  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein / genetics
  • RNA, Messenger
  • Reproductive Techniques, Assisted
  • Retrospective Studies


  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • RNA, Messenger